Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma

2 Dec 2021

Abstract excerpt

Background: Cancer patients with POLE or POLD1 mutations may be excellent candidates for immune checkpoint inhibitors (ICIs) therapy and have favorable prognosis, but their potential in stomach adenocarcinoma (STAD) remains unknown. Therefore, the clinical significance of POLE and POLD1 mutations in STAD was evaluated. Methods: A summary of POLE/POLD1 mutations and clinical characteristics was performed on all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal and Anal Carcinomas
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35261896
DOI: 10.21037/tcr-21-1601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinomaPMID 35261896Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

POLE/POLD1 mutation and tumor immunotherapy.Semantic proximity Read ↗

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapySemantic proximity Read ↗

The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive ReviewSemantic proximity Read ↗

A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.Semantic proximity Read ↗

A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HSemantic proximity Read ↗

Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypesSemantic proximity Read ↗

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumorsSemantic proximity Read ↗

Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world dataSemantic proximity Read ↗

Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.Semantic proximity Read ↗

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.Semantic proximity Read ↗

LHPP is associated with favorable survival across diverse cancers with tumor suppressor properties in stomach adenocarcinoma: a pan-cancer analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.